BI-2536
Drug timelines are a Plus or Pro feature.
10 regulatory and trial events tracked for BI-2536, covering 2013-10-07 to 2024-12-20. Get the full timeline:
Most recent: Clinical Trial Update: Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 1]